![Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire](https://mms.businesswire.com/media/20210107005469/en/739014/5/teva_RGB_JPEG.jpg)
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
![Teva Pharmaceuticals má v Česku a Slovensku nového generálního ředitele - Chemický a farmaceutický průmysl - www.prumysldnes.cz Teva Pharmaceuticals má v Česku a Slovensku nového generálního ředitele - Chemický a farmaceutický průmysl - www.prumysldnes.cz](http://www.prumysldnes.cz/images/Farmacia/teva_pharmaceuticals_logo.jpg)
Teva Pharmaceuticals má v Česku a Slovensku nového generálního ředitele - Chemický a farmaceutický průmysl - www.prumysldnes.cz
EURÓPSKA KOMISIA V Bruseli 28. 1. 2019 COM(2019) 17 final SPRÁVA KOMISIE RADE A EURÓPSKEMU PARLAMENTU PRESADZOVANIE PRÁVA H
![Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire](https://mms.businesswire.com/media/20210831005107/en/739014/23/teva_RGB_JPEG.jpg)